NutriBand Inc. NTRB
of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary
AVERSA™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches
that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.
services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals
Last close
5.97
2026-10-26
Market cap
$72.6M
2026-07-31 share count
52-week range
2.80 - 9.19
Valuation FY2026 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.0M | $2.1M | $2.1M | $2.1M | $1.2M | $737.5K | $370.6K | $245.3K | — |
| Cost of revenue | — | $1.5M | $1.4M | $1.2M | $1.3M | $917.8K | $627.4K | $549.1K | $288.3K | — |
| Gross profit | — | $566.3K | $743.3K | $862.1K | $750.4K | $554.3K | $316.2K | -$178.5K | -$43.0K | — |
| R&D | — | $1.9M | $3.1M | $2.0M | $982.2K | $411.4K | — | — | — | — |
| SG&A | — | $7.0M | $4.3M | $3.8M | $3.9M | $4.0M | $2.9M | $1.8M | $3.3M | $171.9K |
| Total operating expenses | — | $8.9M | $11.0M | $5.7M | $6.6M | $7.5M | $2.9M | $2.3M | $3.6M | $2.7M |
| Operating income | — | -$8.3M | -$10.3M | -$4.9M | -$4.5M | -$6.1M | -$2.6M | -$2.0M | -$3.3M | -$2.7M |
| Interest expense | — | $22.5K | $21.4K | $75.8K | $8.3K | $118.4K | $280.7K | $73.4K | — | — |
| Pre-tax income | — | -$8.2M | -$10.5M | -$5.5M | -$4.5M | -$6.2M | -$2.9M | -$2.7M | -$3.3M | -$2.7M |
| Net income | — | -$8.2M | -$10.5M | -$5.5M | -$4.5M | -$6.2M | -$2.9M | -$2.7M | -$3.3M | -$2.7M |
| EPS, basic | — | -2.58 | -0.99 | -0.69 | -0.53 | -0.80 | -0.51 | — | — | — |
| EPS, diluted | — | -2.58 | -0.99 | -0.69 | -0.53 | -0.80 | -0.51 | -0.50 | -0.62 | -0.14 |
| Shares, diluted (wtd. avg.) | — | 11.6M | 10.6M | 8.0M | 8.5M | 7.9M | 5.8M | — | — | — |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | $4.6M | $4.3M | $492.9K | $2.0M | $4.9M | $152.0K | $10.2K | $474.7K | — |
| Receivables | — | $118.4K | $73.8K | $148.6K | $113.0K | $71.4K | $109.3K | $12.8K | $13.1K | — |
| Inventory | — | $118.0K | $212.0K | $168.6K | $229.3K | $131.6K | $52.8K | — | — | $4.1K |
| Total current assets | — | $5.0M | $4.8M | $1.0M | $2.7M | $5.5M | $314.2K | $43.2K | $590.5K | $164.9K |
| Property, plant and equipment | — | $567.3K | $695.1K | $774.9K | $897.7K | $979.3K | $1.1M | $111.0K | $146.1K | — |
| Goodwill | — | $1.7M | $1.7M | $5.0M | $5.0M | $5.3M | $7.5M | $1.7M | $1.7M | — |
| Other intangibles | — | $200.4K | $261.1K | $667.3K | $780.4K | $926.9K | $1.0M | $314.7K | $351.8K | — |
| Total assets | — | $7.5M | $7.5M | $7.5M | $9.5M | $12.7M | $9.9M | $2.2M | $2.8M | $164.9K |
| Accounts payable | — | $502.7K | $698.8K | $680.1K | $534.7K | $639.5K | $940.6K | $771.9K | $291.8K | $12.3K |
| Short-term debt | — | — | — | $2.0M | — | — | — | — | $0 | $1.8K |
| Total current liabilities | — | $784.3K | $982.8K | $999.1K | $748.6K | $779.3K | $2.6M | $2.0M | $403.0K | $43.4K |
| Long-term debt | — | — | — | — | — | — | — | — | — | $1.8K |
| Total liabilities | — | $868.4K | $1.0M | $1.1M | $883.4K | $880.4K | $2.8M | $2.0M | — | — |
| Retained earnings | — | -$46.7M | -$38.5M | -$28.0M | -$22.5M | -$18.0M | -$11.8M | -$8.9M | -$6.2M | -$2.8M |
| Total equity | — | $6.7M | $6.4M | $6.4M | $8.6M | $11.9M | $7.1M | $175.4K | $2.4M | $121.5K |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$5.1M | -$4.6M | -$3.5M | -$3.0M | -$2.8M | -$297.1K | -$894.5K | -$1.1M | -$92.9K |
| Depreciation and amortisation | — | $133.1K | $171.9K | $174.6K | $330.1K | $308.7K | $160.1K | $91.3K | $37.0K | $0 |
| Stock-based compensation | — | $2.6M | $1.4M | $499.9K | $732.1K | $365.0K | $2.0M | $252.7K | $1.8M | — |
| Capital expenditure | — | $5.3K | $92.0K | $51.8K | $79.3K | $81.6K | — | — | $4.2K | — |
| Investing cash flow | — | -$5.3K | -$92.0K | -$51.8K | -$79.3K | -$81.6K | $67.0K | — | -$404.2K | — |
| Financing cash flow | — | $5.4M | $8.5M | $2.1M | $160.1K | $7.6M | $371.9K | $430.2K | $2.0M | $65.8K |
| Buybacks | — | — | $148.5K | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-058507.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $245.3K | $370.6K | $737.5K | $1.2M | $2.1M | $2.1M | $2.1M | $2.0M | — |
| Gross profit | — | -$43.0K | -$178.5K | $316.2K | $554.3K | $750.4K | $862.1K | $743.3K | $566.3K | — |
| Net income | -$2.7M | -$3.3M | -$2.7M | -$2.9M | -$6.2M | -$4.5M | -$5.5M | -$10.5M | -$8.2M | — |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Charter or fiscal year changed Item 5.03
- Annual report filed Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $159.55B | 57.4x | 20.5% |
| EW | Edwards Lifesciences Corp | $52.20B | 49.5x | 11.5% |
| STE | STERIS plc | $22.44B | 29.0x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.59B | 27.4x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $10.82B | 26.9x | 0.9% |
| MSA | MSA Safety Inc | $7.04B | 25.8x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $1.96B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.31B | 30.0x | 7.5% |